Grant: CIHR - ICR / Cancer Research Society Partnership - Research Grants
University of Alberta
$65,000.00
Precision serology of prostate cancer
FY 2023-24
Summary
Prostate cancer (PCa) is the third leading cause of cancer mortality in men, and novel biomarkers of high-risk PCa are needed. Recently, we developed a novel mass spectrometry method to detect infectious disease antibodies. Our method enabled detection of different types of antibodies in blood. We now propose to extend the use of this novel method to PCa diagnostics based on detection of autoantibodies in blood. We anticipate discovering autoantibodies in PCa, characterization of their structure, and development of a more accurate test to predict high-risk PCa. Novel methods to investigate autoantibodies will enable future studies on novel PCa immunotherapies.
Department
Program
CIHR - ICR / Cancer Research Society Partnership - Research Grants
Recipient
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
510992
Name
Drabovich Andrei P
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
Cancer Research Society Inc.; Cancer Research Society Inc.
Instname2
Cancer Research
Prcname2
Special Cases
Projecttitle
Precision serology of prostate cancer
Programtype2
Operating Grants
Orgnameinp2
University of Alberta
Cihramount2
$65,000
Cihrequipment2
$0
Programname2
CIHR - ICR / Cancer Research Society Partnership - Research Grants
Keyworddelim
Early Career Researchers
Abstract
Prostate cancer (PCa) is the third leading cause of cancer mortality in men, and novel biomarkers of high-risk PCa are needed. Recently, we developed a novel mass spectrometry method to detect infectious disease antibodies. Our method enabled detection of different types of antibodies in blood. We now propose to extend the use of this novel method to PCa diagnostics based on detection of autoantibodies in blood. We anticipate discovering autoantibodies in PCa, characterization of their structure, and development of a more accurate test to predict high-risk PCa. Novel methods to investigate autoantibodies will enable future studies on novel PCa immunotherapies.
Competitiondate
202402
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Drabovich, Andrei P
Approvedterm
2 ans 0 mois
Cihrcontribution2
ICR~ $65,000~ $0~